NEW YORK (GenomeWeb) – Israeli cancer diagnostics developer NovellusDx has raised $10 million in a private financing round.

The round, led by life sciences holding company IntraCure and life sciences venture capital financier Pontifax, includes an option for an additional $10 million investment, the company said in a statement.

Founded in 2012, the firm has developed technology to monitor signaling pathways and identify driver mutations in different kinds of cancer, and monitor the effects of targeted therapies on those mutations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.